Science 37 Holdings (Nasdaq:SNCE) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SNCE Stoklara Genel Bakış

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina.

SNCE temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 91.4% daha düşük bir oranda işlem görüyor

Gelirin yılda 17.47% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( $35M )

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

1 yıldan az nakit akışı var

+ 1 daha fazla risk

Science 37 Holdings, Inc. Rakipler

IsoPlexis

NasdaqGS:ISO

US$30.3m

Bionano Genomics

NasdaqCM:BNGO

US$27.0m

ImmunoPrecise Antibodies

NasdaqGM:IPA

US$12.0m

Rapid Micro Biosystems

NasdaqCM:RPID

US$47.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Science 37 Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$5.75
52 Haftanın En Yüksek Seviyesi	US$12.96
52 Haftanın En Düşük Seviyesi	US$3.73
Beta	0.57
11 Aylık Değişim	1.23%
3 Aylık Değişim	30.39%
1 Yıllık Değişim	30.86%
33 Yıllık Değişim	-97.22%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-97.14%

Son Haberler & Güncellemeler

Recent updates

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Dec 18

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Apr 17

Science 37, Syapse team for faster patient enrollment in cancer trials

Aug 18

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Aug 11

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

May 13

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Apr 11

Science 37: Pioneering Decentralized Clinical Trials

Jan 02

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Nov 04

Hissedar Getirileri

	SNCE	US Life Sciences	US Pazar
7D	0.3%	2.2%	-1.2%
1Y	30.9%	17.2%	30.6%

Getiri vs. Endüstri: SNCE geçen yıl % 17.2 oranında getiri sağlayan US Life Sciences sektörünü aştı.

Getiri vs Piyasa: SNCE geçen yıl boyunca % 30.6 oranında getiri sağlayan US Piyasası ile eşleşti.

Fiyat Oynaklığı

Is SNCE's price volatile compared to industry and market?
SNCE volatility
SNCE Average Weekly Movement	15.6%
Life Sciences Industry Average Movement	7.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: SNCE hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: SNCE 'nin haftalık oynaklığı ( 16% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	460	Dave Coman	www.science37.com

Science 37 Holdings, Inc. Temel Bilgiler Özeti

Science 37 Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SNCE temel i̇stati̇sti̇kler
Piyasa değeri	US$34.67m
Kazançlar(TTM)	-US$124.65m
Gelir(TTM)	US$60.26m

0.6x

P/S Oranı

-0.3x

F/K Oranı

SNCE aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SNCE gelir tablosu (TTM)
Gelir	US$60.26m
Gelir Maliyeti	US$38.14m
Brüt Kâr	US$22.12m
Diğer Giderler	US$146.77m
Kazançlar	-US$124.65m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-20.67
Brüt Marj	36.71%
Net Kâr Marjı	-206.85%
Borç/Özkaynak Oranı	0%

SNCE uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company has been acquired

SNCE Stoklara Genel Bakış

Ödüller

Risk Analizi

Science 37 Holdings, Inc. Rakipler

NasdaqGS:ISO

US$30.3m

NasdaqCM:BNGO

US$27.0m

NasdaqGM:IPA

US$12.0m

NasdaqCM:RPID

US$47.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Science 37 Holdings, Inc. Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Holdings, Inc. Metasite Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Holdings, Inc. Delivers 22x Faster Enrollment Than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Holdings Files Form 15

Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index

eMed, LLC completed the acquisition of Science 37 Holdings, Inc. (NasdaqCM:SNCE).

Recent updates

Science 37 Holdings, Inc. Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Holdings, Inc. Metasite Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Holdings, Inc. Delivers 22x Faster Enrollment Than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Holdings Files Form 15

Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index

eMed, LLC completed the acquisition of Science 37 Holdings, Inc. (NasdaqCM:SNCE).

eMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc. (NasdaqCM:SNCE) $37.8 million.

Price target decreased by 51% to US$13.83

eMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc. (NasdaqCM:SNCE) $37.8 million.

New major risk - Share price stability

Forecast to breakeven in 2026

Science 37 Holdings Regains Compliance with Minimum Closing Bid Price Requirement for Continued Listing on NASDAQ Capital Market

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Science 37 Holdings, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023

Price target decreased by 20% to US$1.50

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Science 37 Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CEO & Director exercised options and sold US$64k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Science 37 Holdings, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Science 37 Holdings Announces Nasdaq Approves an Additional 180 Calendar Day Compliance Period to Regain Compliance with the Minimum Bid Requirement

Consensus estimates of losses per share improve by 11%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Price target decreased by 9.4% to US$1.81

High number of new and inexperienced directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Science 37 Holdings, Inc. (NasdaqGM:SNCE) acquired Life Sciences Platform of Vault Health.

Science 37 Holdings Receives A Deficiency Notification Letter from Nasdaq Regarding Minimum Bid Price

Consensus revenue estimates fall by 15%

Price target decreased to US$3.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Science 37 Holdings, Inc. Revises Earnings Guidance for the Full Year 2022

Science 37 Holdings, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Science 37 Holdings, Inc. Announces Board Changes

Science 37®Holdings, Inc. Announces Changes to its Board

Science 37 Holdings, Inc. Appoints Michael Shipton as Chief Commercial Officer

Science 37 Holdings, Inc. and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical Trials

Consensus forecasts updated

Science 37, Syapse team for faster patient enrollment in cancer trials

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Science 37 Holdings, Inc. Provides Revenue Guidance for Year Ending December 31, 2022

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Science 37 Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Oncology Clinical Trial Execs to Increase Decentralization, Science 37 Survey Indicates

Consensus estimates of losses per share improve by 72%

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Science 37 Introduces Virtual Site Model to Rescue Slow Enrolling Clinical Trials

Science 37® Announces NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct

First quarter 2022 earnings: Revenues exceed analyst expectations

Science 37 Holdings, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

Price target decreased to US$11.33

Science 37 Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Science 37 Holdings, Inc. Adds Shaalan Beg to Its Global Management Team